OverviewSuggest Edit

Novartis is a company that researches, develops, manufactures, and markets healthcare products. It comprises 2 global operation divisions: Innovative Medicines and Sandoz. The Innovative Medicines division offers patented prescription medicines, commercializes products in the areas of oncology and rare diseases, ophthalmology, immunology and dermatology, neuroscience, respiratory, cardio-metabolic, and established medicines. The Sandoz division provides active ingredients and finished dosage forms of pharmaceuticals in the areas of the cardiovascular, central nervous system, dermatology, gastrointestinal and hormonal therapies, metabolism, oncology, ophthalmic, and respiratory.
TypePublic
Founded1996
HQBasel, CH
Websitenovartis.com
Employee Ratings4.2
Overall CultureA+

Latest Updates

Employees (est.) (Dec 2020)105,794(+2%)
Job Openings1,817
Revenue (FY, 2020)$48.7 B(+3%)
Share Price (Jul 2021)CHF83.9
Cybersecurity ratingAMore

Key People/Management at Novartis

Vasant Narasimhan

Vasant Narasimhan

Chief Executive Officer
Joerg Reinhardt

Joerg Reinhardt

Chairman
James Bradner

James Bradner

President of the Novartis Institutes for BioMedical Research (NIBR)
Karen L. Hale

Karen L. Hale

Chief Legal Officer
Harry Kirsch

Harry Kirsch

Chief Financial Officer
Shannon Thyme Klinger

Shannon Thyme Klinger

Chief Legal Officer
Show more

Novartis Office Locations

Novartis has offices in Basel, Pratteln, Stein, Broomfield and in 165 other locations
Basel, CH (HQ)
Fabrikstrasse 2
Basel, CH
210, Lichtstrasse 35
Pratteln, CH
Schweizerhalle, Rheinstrasse 52
Stein, CH
Schaffhauserstrasse 101
Tirana, AL
Rruga Hoxha Tahsim 23
Bir Mourad Raïs, DZ
69 Zone d´Activité Said Hamdine
Show all (185)

Novartis Financials and Metrics

Novartis Revenue

Embed Graph
View revenue for all periods
Novartis's revenue was reported to be $48.66 b in FY, 2020 which is a 2.6% increase from the previous period.
USD

Revenue (FY, 2020)

48.7b

Revenue growth (FY, 2019 - FY, 2020), %

2.6%

Gross profit (FY, 2020)

33.5b

Gross profit margin (FY, 2020), %

68.9%

Net income (FY, 2020)

8.1b

EBIT (FY, 2020)

10.2b

Market capitalization (30-Jul-2021)

188.3b

Closing stock price (30-Jul-2021)

83.9

Cash (31-Dec-2020)

9.7b

EV

216.7b
Novartis's current market capitalization is CHF188.3 b.
Annual
USDFY, 2018FY, 2019FY, 2020

Revenue

51.9b47.4b48.7b

Revenue growth, %

6%(9%)3%

Cost of goods sold

17.1b13.2b15.1b

Gross profit

34.8b34.2b33.5b
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

12.7b13.2b12.8b11.1b11.8b12.2b12.3b11.3b12.3b

Cost of goods sold

4.1b4.2b4.3b3.0b3.1b3.5b3.3b3.2b3.8b

Gross profit

8.6b9.0b8.5b8.2b8.6b8.7b9.0b8.2b8.5b

Gross profit Margin, %

68%68%66%73%73%72%73%72%69%
Annual
USDFY, 2018FY, 2019FY, 2020

Cash

13.3b11.1b9.7b

Accounts Receivable

8.7b8.3b8.2b

Inventories

7.0b6.0b7.1b

Current Assets

35.6b29.5b29.7b
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

5.8b12.4b14.0b6.8b10.0b8.4b4.5b5.9b9.0b

Accounts Receivable

8.9b8.8b8.6b7.6b8.0b7.8b8.5b7.6b8.1b

Inventories

7.2b7.1b7.0b5.7b6.1b6.1b6.4b6.9b7.1b

Current Assets

33.1b32.1b34.1b52.4b28.3b26.7b23.1b23.9b29.0b
Annual
USDFY, 2018FY, 2019FY, 2020

Net Income

12.6b7.1b8.1b

Depreciation and Amortization

6.9b5.8b6.1b

Inventories

(533.0m)(382.0m)(543.0m)

Accounts Payable

309.0m553.0m(324.0m)
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

2.0b9.8b11.4b1.9b4.0b6.0b2.2b4.0b6.0b

Depreciation and Amortization

4.9b1.4b2.5b3.9b1.4b3.1b

Cash From Operating Activities

2.5b6.5b10.5b2.4b5.5b10.1b2.5b6.5b9.6b

Purchases of PP&E

(359.0m)(690.0m)(1.1b)(282.0m)(561.0m)(918.0m)(237.0m)(475.0m)(754.0m)
USDQ1, 2018

Debt/Equity

0.5 x

Debt/Assets

0.3 x

Financial Leverage

1.9 x
Show all financial metrics

Novartis Operating Metrics

FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Major Approvals (US, EU, JP)

20161615

Major Submissions (US, EU, JP)

1424162030

Patients Reached

972 m965 m927 m

Projects Entering Development Pipeline

859
Show all operating metrics

Novartis Acquisitions / Subsidiaries

Company NameDateDeal Size
Vedere BioOctober 29, 2020$280 m
AmblyotechApril 21, 2020
The Medicines CompanyNovember 25, 2019$9.7 b
XiidraMay 09, 2019$1.9 b
Novartis Inflammasome ResearchApril 02, 2019$1.58 b
CellforCureDecember 21, 2018
EndocyteOctober 18, 2018
AveXisApril 09, 2018$8.7 b
Advanced Accelerator ApplicationsOctober 30, 2017$3.9 b
Encore VisionDecember 20, 2016
Show more

Novartis Revenue Breakdown

Embed Graph

Novartis revenue breakdown by business segment: 19.8% from Sandoz and 80.2% from Innovative Medicines

Novartis revenue breakdown by geographic segment: 5.3% from China, 5.8% from Japan , 33.9% from United States, 5.0% from France, 9.3% from Germany and 40.8% from Other

Human Capital Metrics

Embed Graph
Show all human capital metrics

Novartis Cybersecurity Score

Cybersecurity ratingPremium dataset

A

94/100

SecurityScorecard logo

Novartis Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

60-79

out of 100

CSRHub logo

Novartis Online and Social Media Presence

Embed Graph

Novartis Company Culture

  • Overall Culture

    A+

    82/100

  • CEO Rating

    A+

    84/100

  • Compensation

    A+

    90/100

  • Diversity

    A+

    83/100

Learn more on Comparably

Novartis News and Updates

快讯 | 诺华2021半年报发布:上半年净利润同比增长23%,中国区累计收入15.55亿美元

财经网产经讯 诺华公布2021半年报,上半年实现营收253.67亿美元,同比增长7%,净利润49.54亿美元,同比增长23%。

Hedge Funds Never Been Less Bullish On Novartis AG (NVS)

The financial regulations require hedge funds and wealthy investors that exceeded the $100 million holdings threshold to file a report that shows their positions at the end of every quarter.

Novartis partners with 26 HBCUs to invest more than $37 million into healthcare equity

Novartis is donating to a number of historically Black academic institutions to help solve inequalities in healthcare and education.

Novartis profit tops expectations as pandemic impact ebbs

Swiss drugmaker Novartis beat second-quarter sales and profit expectations on Wednesday, while keeping its 2021 guidance unchanged, as disruption from the coronavirus pandemic waned.

Novartis delivered strong Q2 performance, driven by momentum of key growth brands. FY 2021 guidance unchanged.

Novartis delivered a strong second quarter, driven by the momentum of our key growth brands, including Cosentyx, Entresto, Zolgensma, our Oncology portfolio and the launch of Kesimpta which continues to accelerate.
Show more

Novartis Frequently Asked Questions

  • When was Novartis founded?

    Novartis was founded in 1996.

  • Who are Novartis key executives?

    Novartis's key executives are Vasant Narasimhan, Joerg Reinhardt and James Bradner.

  • How many employees does Novartis have?

    Novartis has 105,794 employees.

  • What is Novartis revenue?

    Latest Novartis annual revenue is $48.7 b.

  • What is Novartis revenue per employee?

    Latest Novartis revenue per employee is $459.9 k.

  • Who are Novartis competitors?

    Competitors of Novartis include Bausch + Lomb, Immunomedics and Gilead Sciences.

  • Where is Novartis headquarters?

    Novartis headquarters is located at Fabrikstrasse 2, Basel.

  • Where are Novartis offices?

    Novartis has offices in Basel, Pratteln, Stein, Broomfield and in 165 other locations.

  • How many offices does Novartis have?

    Novartis has 185 offices.